GlassScriptPhysician profile
Leah Jones
NPI 1821484288
$9,630.60
in general payments reported to CMS, 2019-2025
29 companies · $2,703 in 2025
The $2,703 reported for 2025 was more than what 92% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $17.72 · 2021: $693 · 2022: $1,034 · 2023: $1,828 · 2024: $3,355 · 2025: $2,703.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,787 · Education: $99.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,786.61 |
| Education | $99.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Supernus Pharmaceuticals, INC. | $1,718.92 | 2022-2025 | Qelbree, Qelbree |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $993.97 | 2021-2025 | Caplyta |
| Abbvie INC. | $953.45 | 2021-2025 | |
| Tris Pharma INC | $813.83 | 2022-2025 | Dyanavel Xr, Onyda Xr, Quillivant |
| Otsuka America Pharmaceutical, INC. | $723.16 | 2020-2025 | Rexulti |
| Janssen Pharmaceuticals, INC | $626.54 | 2021-2025 | Spravato, Invega Sustenna |
| Corium, LLC | $597.04 | 2021-2025 | Azstarys |
| Axsome Therapeutics, INC. | $388.94 | 2023-2025 | Auvelity |
| Lundbeck LLC | $377.57 | 2021-2025 | Rexulti |
| Noven Therapeutics, LLC | $354.86 | 2023-2025 | Xelstrym |
| Bausch Health US, LLC | $282.11 | 2021-2025 | Aplenzin, Wellbutrin |
| Teva Pharmaceuticals USA, INC. | $271.63 | 2022-2025 | Austedo Xr, Austedo Xr |
| Ironshore Pharmaceuticals INC. | $257.08 | 2022-2024 | Jornay Pm |
| Takeda Pharmaceuticals U.S.A., INC. | $241.06 | 2021-2025 | Trintellix |
| Neurocrine Biosciences, INC. | $156.22 | 2022-2025 | Ingrezza |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Collegium Pharmaceutical, INC. | $140.95 | 2025 | Jornay Pm |
| Vanda Pharmaceuticals INC. | $128.63 | 2021-2023 | Hetlioz, Fanapt |
| Idorsia Pharmaceuticals US INC | $108.11 | 2022-2024 | Quviviq |
| Alfasigma USA, INC. | $92.18 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $66.47 | 2022 | |
| Sunovion Pharmaceuticals INC. | $57.21 | 2021-2022 | |
| Sandoz INC. | $49.49 | 2024 | Hyrimoz |
| Eisai INC. | $49.09 | 2021 | |
| Brainsway USA INC | $42.88 | 2023 | |
| Jazz Pharmaceuticals INC. | $39.24 | 2021 | |
| Adlon Therapeutics L.P. | $30.53 | 2021 | |
| Alkermes, INC. | $24.52 | 2025 | Aristada, Lybalvi |
| Tempus Ai, INC | $24.04 | 2024 | |
| E.R. Squibb & Sons, L.L.C. | $20.88 | 2025 | Cobenfy |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Leah Jones listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.